ArticleEuropean journal of pediatrics2025
Elevated serum METRNL levels in children with obesity and its association with insulin resistance.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Meteorin-like protein (METRNL) has emerged as a novel adipokine involved in metabolic regulation. However, its role in pediatric obesity and its relationship with insulin resistance remain largely unexplored. In this cross-sectional study, we enrolled 55 children with obesity (34 boys, 21 girls) and 49 normal-weight controls (31 boys, 18 girls). Serum levels of METRNL, inflammatory markers (IL-6, TNF-α), and adipokines (leptin, adiponectin) were measured. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance. Correlations between METRNL and metabolic parameters were analyzed, and multiple regression analysis was performed to identify factors independently associated with insulin resistance. Serum METRNL levels were significantly higher in children with obesity compared to controls (4.62 ± 1.24 vs 2.84 ± 0.76 ng/mL, p < 0.05). METRNL levels showed positive correlations with BMI (r = 0.624, p < 0.05), HOMA-IR (r = 0.594, p < 0.05), inflammatory markers (IL-6: r = 0.528, p < 0.05; TNF-α: r = 0.486, p < 0.05), and leptin (r = 0.546, p < 0.05), while negatively correlating with adiponectin (r = - 0.482, p < 0.05). Multiple regression analysis revealed that METRNL was independently associated with HOMA-IR (standardized β = 0.384, p < 0.05) after adjusting for potential confounders.
conclusionSerum METRNL levels are elevated in children with obesity and independently associated with insulin resistance. These findings suggest that METRNL might play a significant role in the pathophysiology of pediatric obesity and its metabolic complications. WHAT IS KNOWN: • Meteorin-like protein (METRNL) has emerged as a novel adipokine involved in metabolic regulation. WHAT IS NEW: • Serum METRNL concentrations were significantly elevated in children with obesity. • METRNL levels showed positive correlations with BMI, HOMA-IR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.